Alnylam files patent infringement suits against Pfizer, Moderna
Reprints
(Reuters) – Alnylam Pharmaceuticals Inc. said on Thursday it has filed separate lawsuits in the Delaware federal court against Pfizer Inc. and Moderna Inc., seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.
Alnylam said it was seeking compensation for use of its lipid nanoparticles technology that carries and delivers RNA-based therapeutics or vaccines in the body.
Pfizer and Moderna's vaccines infringe Alnylam's patent through the use of a lipid formulated into LNPs that protect and deliver the vaccines' mRNA, the pharmaceutical firm said.
Arbutus Biopharma Corp. sued Moderna in the Delaware federal court last month, claiming Moderna's COVID-19 vaccine infringes its patents.
Alnylam said it does not intend to take action that impedes the production, sale or distribution of the vaccines.
Read Next
-
FDA grants full approval to Pfizer-BioNTech COVID-19 vaccine
(Reuters) — The U.S. Food and Drug Administration on Monday gave full approval to the COVID-19 vaccine made by Pfizer Inc. and German partner BioNTech SE for use in people over the age of 16.
Related Stories
-
FDA grants full approval to Pfizer-BioNTech COVID-19 vaccine
-
Amazon, Pfizer, Astra Zeneca collaborate in health care innovation lab
-
Court revives suit against Pfizer, others on Iraq terrorism funding claims
Most Read in Workers Comp
-
1. Zurich ordered to pay $80 million in suit over employee incentives
-
3. Marsh McLennan sees rate hikes slowing; reports revenue growth
-
4. Travelers sees rate hikes continue; Q1 profit up over 15%
-
5. DeSantis signs legislation prohibiting local workplace heat protections
-
6. AI not a ‘substitute,’ but can benefit insurance industry: Experts
